—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Novo Nordisk A/S (NVO) — chart, structure and Closelooknet read

The Closelooknet read

Novo Nordisk researches, manufactures and distributes pharmaceutical products through two units: Obesity and Diabetes Care, and Rare Disease. The first covers diabetes, obesity, cardiovascular and related conditions, including GLP-1 therapies such as Wegovy alongside insulin pens and dosing apps.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Our record on NVO

Every scored call, pick and trade this diary has made on Novo Nordisk A/S, with the outcome where it is known.

Signals for this name

Every Closelooknet reading that exists for NVO, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-11-05

DayWeekMonth3 months
NVO−4.5%+3.0%+5.3%−14.7%
Longevity & Healthspan−3.9%−3.5%+2.7%—
HALO Growth 100−2.8%−1.2%+0.4%—

Against the index: 4.2 pts ahead on the week, 4.9 pts ahead on the month; against its Longevity & Healthspan sleeve 2.6 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Mentioned on Closelooknet 1 piece · newest: Midday 10, “Midterms — Dow Jumps 2.3% and Apple Hits a Record; Data-Center Power Stocks Sink Up to 15%” (2026-11-04)

Mentioned on Closelooknet

Where NVO appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 44/100 · S&P 500 fund at 48, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-05
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 73th percentile of the window, -21.7% over 20 sessions. Factor regime → 2026-11-04
  • Sector × region Health care in Europe: +4.3% week · +15.0% month · +10.3% quarter · +12.1% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-05
  • Sovereign pressure Index -2.05 · down 2.95 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-05
How it trades on rate days beta 0.54 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How NVO has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.54 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Novo Nordisk A/S moved 0.54% on average · correlation 0.11 · higher than 49% of US names
  • Beta, last 3 months 1.08 more rate-sensitive lately than over the year
  • On the 10 worst bond days −1.08% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.18% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against NVO on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Novo Nordisk A/S

NVO in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Novo Nordisk researches, manufactures and distributes pharmaceutical products through two units: Obesity and Diabetes Care, and Rare Disease. The first covers diabetes, obesity, cardiovascular and related conditions, including GLP-1 therapies such as Wegovy alongside insulin pens and dosing apps. The Rare Disease unit covers rare blood and endocrine disorders and hormone replacement. It sells across Europe, the Americas, Asia, the Middle East and Africa from its base in Denmark.
Where it sits in the stack
Novo Nordisk sits in the Longevity & Healthspan sleeve of our HALO Growth 100, the growth index Closelooknet tracks outside the megacaps. That sleeve groups companies whose demand is set by ageing and chronic-disease trends rather than by a single product cycle.
Who it is priced against
Closelooknet's peer group places it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders, including Eli Lilly, Regeneron, Zealand Pharma, Vertex, Illumina, Amgen, Natera and Gerresheimer; the market also names Pfizer as a comparator in the obesity-drug race.
Why Closelooknet tracks it
It holds a seat in the HALO Growth 100 and carries a Closelooknet score, with quality the strongest module and growth the weakest; the diary has not yet quoted it in an edition.
What the diary watches
Whether the growth module recovers as the obesity-drug pipeline advances, and whether the gap to the 50- and 200-day chart levels narrows or widens.

Novo Nordisk A/S (NVO) trades on US exchanges in Denmark, classified under Healthcare. Constituent of HALO Growth 100.

The Closelooknet company score reads 55/100 composite (momentum 28, quality 86, valuation 75) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 0 analyst actions on the wire · last print 2026-11-04

The Street on this name

Analyst actions and the latest print for NVO from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Latest print EPS 0.89 against 0.73 expected — a +21.8% beat 2026-11-04

Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 4.60%, semi-annual · buybacks 1.39 bn USD in FY2025

Dividends and capital return

What NVO pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 1.85 USD per share · a 4.60% yield on the 2026-11-05 close 2 distributions, paid twice a year 2026-11-05
  • Change on the year +10.2% against the prior twelve months prior twelve months 1.68 USD per share
  • Last distribution 0.58 USD per share as the price series records it, within days of the ex-date 2026-08-17
  • By calendar year 2024: 1.44 USD (partial) · 2025: 1.68 USD · 2026: 1.85 USD to date first distribution recorded in the three-year window: 2024-03-22
  • Dividends paid, FY2025 51.8 bn USD 13% of earnings
  • Buybacks, FY2025 1.39 bn USD 0.8% of today's market value
  • Share count −0.3% in FY2025
  • Capital returned 53.2 bn USD · 183% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-06

Quick answers

What is Novo Nordisk A/S (NVO)?

Novo Nordisk A/S trades as NVO on the US exchange (Denmark) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-06.

Is NVO in a Closelooknet index?

Yes — Novo Nordisk A/S is a constituent of HALO Growth 100, as of 2026-11-06.

What is Novo Nordisk A/S's Closelooknet composite score?

55 out of 100, with momentum 28, quality 86 and valuation 75 sub-scores, as of 2026-11-06. Scores are Closelooknet's own research readings, not ratings or investment advice.

What is Novo Nordisk A/S's earnings print record?

Across the 10 prints Closelooknet covers, Novo Nordisk A/S beat EPS estimates 8 times and revenue estimates 8 times; the three-day reactions split 4 up, 4 flat and 2 down (moves beyond ±3%), as of the 2026-11-03 card. The full print-record card carries the per-print history.

Where does NVO trade against its moving averages?

Novo Nordisk A/S trades 3.3% above its 50-day and 3.1% below its 200-day moving average (7.7% above its 20-day). As of 2026-11-04 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is NVO doing against its Closelooknet index?

Over the past month Novo Nordisk A/S is +5.3% against +0.4% for the HALO Growth 100 — 4.9 points ahead of its index, as of 2026-11-05. Its Longevity & Healthspan sleeve is +2.7% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Novo Nordisk A/S compare with its peers?

Against its peer group (HALO Growth 100 · Longevity & Healthspan), Novo Nordisk A/S (NVO) sits 31.8% below its 52-week high, 3.3% above its 50-day average; Regeneron Pharmaceuticals Inc (REGN) is 6.2% below, Vertex Pharmaceuticals Inc (VRTX) is 3.5% below, Zealand Pharma A/S (ZEAL.CO) is 57.4% below, as of 2026-11-04. Put any of them next to NVO in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Novo Nordisk A/S trade when bond yields rise?

Over the past year Novo Nordisk A/S had a beta of 0.54 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 49% of US names. On the 10 sessions in which long bonds fell most it moved −1.08% on average, against −0.74% for the S&P 500. As of 2026-11-05; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Novo Nordisk A/S?

Novo Nordisk A/S appears in 1 Closelooknet piece as of 2026-11-06, most recently Midday 10: Midterms — Dow Jumps 2.3% and Apple Hits a Record; Data-Center Power Stocks Sink Up to 15% (2026-11-04). What Closelooknet said most recently: Novo Nordisk — outlook raised, shares up 6% (Midday 10, 2026-11-04). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Novo Nordisk A/S do?

Novo Nordisk researches, manufactures and distributes pharmaceutical products through two units: Obesity and Diabetes Care, and Rare Disease. The first covers diabetes, obesity, cardiovascular and related conditions, including GLP-1 therapies such as Wegovy alongside insulin pens and dosing apps. The Rare Disease unit covers rare blood and endocrine disorders and hormone replacement. Closelooknet's peer group places it with GLP-1 leaders, gene-editing platforms, diagnostics-at-scale and biopharma compounders, including Eli Lilly, Regeneron, Zealand Pharma, Vertex, Illumina, Amgen, Natera and Gerresheimer; the market also names Pfizer as a comparator in the obesity-drug race. (Company snapshot of 2026-09-17.)

Where does Novo Nordisk A/S sit in the AI build-out?

Novo Nordisk sits in the Longevity & Healthspan sleeve of our HALO Growth 100, the growth index Closelooknet tracks outside the megacaps. That sleeve groups companies whose demand is set by ageing and chronic-disease trends rather than by a single product cycle. It holds a seat in the HALO Growth 100 and carries a Closelooknet score, with quality the strongest module and growth the weakest; the diary has not yet quoted it in an edition. (Company snapshot of 2026-09-17.)

Does Novo Nordisk A/S pay a dividend?

Novo Nordisk A/S has paid 1.85 USD per share over the last twelve months, paid twice a year, a trailing yield of 4.60% on the 2026-11-05 close; the last distribution recorded in the price series was 0.58 USD on 2026-08-17. In fiscal 2025 the company paid 51.8 bn USD in dividends and bought back 1.39 bn USD of its own shares, 183% of that year’s free cash flow. The share count fell 0.3% over the fiscal year. As of 2026-11-05; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Novo Nordisk A/S recently?

Its latest earnings print on the wire, 2026-11-04: EPS 0.89 against 0.73 expected — a +21.8% beat. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for NVO, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

same Closelooknet index seat first, then Drug Manufacturers - General. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.